A Comparative Study of Entecavir vs. Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Subjects: The DEFINE Study.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Adefovir dipivoxil (Primary) ; Entecavir (Primary) ; Lamivudine; Tenofovir disoproxil fumarate
Indications Hepatitis B
Focus Therapeutic Use
Acronyms DEFINE

10 Nov 2012 Status changed from active, no longer recruiting to completed.
03 Jul 2012 Actual patient number is 629 as reported by ClinicalTrials.gov.
18 Nov 2011 Planned end date changed from 1 Jun 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com